TITLE

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

AUTHOR(S)

Gruenberger, Birgit; Scheithauer, Werner; Punzengruber, Robert; Zielinski, Christoph; Tamandl, Dietmar; Gruenberger, Thomas

PUB. DATE

January 2008

SOURCE

BMC Cancer;2008, Vol. 8, Special section p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: Surgical resection of liver metastases arising from colorectal cancer is considered the only curative treatment option. However, many patients subsequently experience disease recurrence. We prospectively investigated whether neoadjuvant chemotherapy reduces the risk of recurrence following potentially curative liver resection. Special emphasis was directed to the importance of response. Methods: 50 patients with resectable liver metastases received neoadjuvant XELOX or FOLFOX4 for six cycles (3 months). Complete resection of liver metastases was intended thereafter. Assessments included response rate, postoperative morbidity and recurrence-free survival. Results: An objective response was observed in 72% of all patients, including two complete responses. Chemotherapy was well tolerated and the majority of adverse events were mild to moderate (grade 1/2). Potentially curative R0 resection was performed in all patients and postoperative complications were observed in only 12%. The median recurrence-free survival was significantly influenced by tumor response with 24.7 months (95% CI: 4.50 to 44.97) in responding patients, 8.2 months (95% CI: 3.09 to 13.31) in patients with stable disease and 3.0 months (95% CI: 0 to 8.91) in patients with progressive disease. Conclusion: These data suggest that neoadjuvant Oxaliplatin based chemotherapy provides high response rates without increased risk of perioperative morbidity. Response to chemotherapy can lead to long-term recurrence-free survival. Neoadjuvant chemotherapy may identify best candidates for a potentially curative treatment approach.

ACCESSION #

35703987

 

Related Articles

• Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. Chua, Terence; Bester, Lourens; Saxena, Akshat; Morris, David // Journal of Cancer Research & Clinical Oncology;May2011, Vol. 137 Issue 5, p865 

  Purpose: To evaluate the role of radioembolization and systemic chemotherapy as a combined modality therapy for unresectable colorectal liver metastases. Patients and methods: Prospective database of a major yttrium-90 microsphere radioembolization treatment center in Sydney, Australia, that...

• IS3–4INTENSIVE CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER (MCRC). Ychou, M. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix14 

  No abstract available.

• Letter to the editor: the benefit of adjuvant chemotherapy for resectable colorectal cancer liver metastases. Zhong, Chen; Li, Kainan; Bi, Jingwang; Wang, Baocheng // International Journal of Colorectal Disease;Oct2013, Vol. 28 Issue 10, p1455 

  A letter to the editor which examines the benefits of adjuvant chemotherapy for treating patients with colorectal cancer (CRC)-induced liver metastases is presented.

• Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial. Martin, Robert; Scoggins, Charles; Tomalty, Dana; Schreeder, Marshall; Metzger, Tiffany; Tatum, Clifton; Sharma, Vivek // Journal of Gastrointestinal Surgery;Aug2012, Vol. 16 Issue 8, p1531 

  Purpose: The primary objective of this study is to evaluate the safety, tolerance, and pharmacokinetic profile of liver-directed therapy with drug-eluting beads irinotecan (DEBIRI) in combination with systemic modified FOLFOX in the treatment of unresectable liver metastases in...

• Modern management of colorectal liver metastases. Krige, J. E. J.; Bernon, M.; Beningfield, J. // CME: Continuing Medical Education;Jun2013, Vol. 31 Issue 6, p197 

  The article discusses techniques used in managing liver metastases in colorectal cancer patients. To extend survival, patients with colorectal liver metastasis need to undergo surgical resection based on the recognition that colorectal tumour cells initially spread haematogenously via the portal...

• The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer. Sumito Sato; Hiroshi Nakano; Yasuo Ishida; Takehito Otsubo // Journal of Gastrointestinal Oncology;Jun2013, Vol. 4 Issue 2, p203 

  Background: Oxaliplatin-based chemotherapy for colorectal liver metastasis can induce hepatotoxicity, which increases the risk of liver resection. We previously reported that the aspartate aminotransferase to platelet ratio (APR) before chemotherapy can indicate oxaliplatin-induced splenomegaly...

• The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. Sarfati, Diana; Hill, Sarah; Blakely, Tony; Robson, Bridget; Purdie, Gordon; Dennett, Elizabeth; Cormack, Donna; Dew, Kevin // BMC Cancer;2009, Vol. 9, Special section p1 

  Background: Comorbidity has a well documented detrimental effect on cancer survival. However it is difficult to disentangle the direct effects of comorbidity on survival from indirect effects via the influence of comorbidity on treatment choice. This study aimed to assess the impact of...

• Current topics in colorectal liver metastasis. Sakai, Yoshiharu // International Journal of Clinical Oncology;Oct2011, Vol. 16 Issue 5, p451 

  No abstract available.

• Microinvasion of liver metastases from colorectal cancer: predictive factors and application for determining clinical target volume. Yang Qian; Zhao-Chong Zeng; Yuan Ji; Yin-Ping Xiao // Radiation Oncology;2015, Vol. 10 Issue 1, p1 

  Objectives: This study evaluates the microscopic characteristics of liver metastases from colorectal cancer (LMCRC) invasion and provides a reference for expansion from gross tumor volume (GTV) to clinical targeting volume (CTV). Methods: Data from 129 LMCRC patients treated by surgical...

Read the Article